Status:
UNKNOWN
Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System
Lead Sponsor:
National and Kapodistrian University of Athens
Conditions:
COVID-19
Healthy Volunteers
Eligibility:
All Genders
18+ years
Brief Summary
Determination of both the degree and duration of the immunity provided after receiving the BNT162b2 vaccine against SARS-Cov-2.
Detailed Description
The purpose of this study is to assess the kinetics of antibodies against SARS-CoV-2 as well as the kinetics of the immune system's cell subpopulations and cytokines associated with the immune system ...
Eligibility Criteria
Inclusion
- Healthy volunteers and all individuals who, according to the instructions of the Greek State are considered eligible to receive the BNT162b2 vaccine
- Age ≥ 18 years old
Exclusion
- Serious allergy problems i.e. hospitalization due to a serious allergic reaction (anaphylaxis)
Key Trial Info
Start Date :
January 4 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04743388
Start Date
January 4 2021
End Date
December 1 2022
Last Update
April 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical Therapeutics, General Hospital of Athens ALEXANDRA
Athens, Greece